Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10306093 | 0.89 | RORC (0.44) | RORCPDE4BHTTSMN1; SMN2NPC1 | |
| SCHEMBL10306090 | 0.89 | RORC (0.44) | RORCPDE4BHTTSMN1; SMN2NPC1 | |
| SCHEMBL3975601 | 0.89 | RORC (0.44) | RORCPDE4BHTTSMN1; SMN2NPC1 | |
| SCHEMBL3976887 | 0.89 | RORC (0.44) | RORCPDE4BHTTSMN1; SMN2NPC1 | |
| SCHEMBL3975071 | 0.89 | RORC (0.44) | RORCPDE4BHTTSMN1; SMN2NPC1 | |
| SCHEMBL3976224 | 0.88 | RORC (0.44) | RORCPDE4BHTTSMN1; SMN2NPC1 | |
| SCHEMBL3976228 | 0.88 | RORC (0.44) | RORCPDE4BHTTSMN1; SMN2NPC1 | |
| SCHEMBL10306101 | 0.88 | RORC (0.44) | RORCPDE4BHTTSMN1; SMN2NPC1 | |
| SCHEMBL3975384 | 0.87 | RORC (0.43) | RORCPDE4BHTTSMN1; SMN2NPC1 | |
| SCHEMBL3974998 | 0.87 | PDE4B (0.46) | RORCPDE4BHTTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882689-B1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8211910-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| EP-2463274-A1 | Tri-or tetra-substituted-3-aminopyrrolidine deritatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7563805-B2 | 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| EP-1882689-A1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | QTRT1, RRS1, LAS1L | RORC 230/4885PDE4B 1673/4885HTT 3414/4885 |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | AAAS, NPEPPS, TEAD4 | RORC 993/4885PDE4B 2230/4885HTT 4125/4885 |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | TLR5, TEAD4, NAALAD2 | RORC 1578/4885PDE4B 1717/4885HTT 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.